Runny nose

Bacillus cereus ip 5832 biochemical properties. Bactisubtil

Bacteria are the simplest form of life, consisting of a single cell. They reproduce very quickly by division. The bacterium, when mature, divides into two cells, resulting in two microorganisms. The whole process takes approximately 20-30 minutes. Then it is repeated many times. At such a tremendous speed, one bacterium, under ideal conditions, could produce about 33 trillion offspring per day. New strains of bacteria - pure cultures isolated at a specific time and place - will appear very quickly at this rate of reproduction. But their life is not so long. It ranges from several minutes to a couple of hours in different species, so bacteria, even under ideal conditions, cannot multiply so quickly.

Listeria monocytogenes

These organisms appeared on earth long before humans, due to which the number of their varieties is now incredibly large. For ease of study, they are divided into strains, combining according to their properties and characteristics.

To understand how diverse they are, you can evaluate the temperatures that are comfortable for the existence of various bacteria. There is a temperature at which all organisms of this species cease to be active and hibernate. There is also an upper threshold at which they die. In the interval between these temperatures, bacteria feel very comfortable and are active.

Thus, for saprophytic bacteria (feeding on the cells of dead plants or animals), the temperature range is very small - from +25°C to +30°C. For pathogenic microorganisms that cause diseases, the optimal temperature is +38°C. There are also bacteria that live and reproduce well at temperatures of +100°C. The diversity of bacteria on Earth is very large.

Strains

In microbiology, the science that studies microorganisms (individuals invisible to the eye), there is the concept of a bacterial strain. A strain is a pure culture of microorganisms. Since bacteria reproduce by division, most often entire colonies of similar microorganisms are found. Due to their high reproduction rate, these creatures are very variable. Therefore, the same strain of bacteria cannot be isolated from the same source twice.

Lactic acid bacteria

Since ancient times, fermented milk products have been produced using strains of lactic acid bacteria. These organisms ferment carbohydrates, producing lactic acid. Recently, they are not only used to prepare fermented milk products, but also added to food.

Strains of lactic acid bacteria are mainly probiotic and remain viable when passing through the gastrointestinal tract. They have many useful properties. For example, they are active against pathogenic microorganisms, producing various organic acids with bactericidal action. And some strains produce active hydrogen peroxide, which destroys viruses.

Nodule bacteria

A strain of nodule bacteria is also isolated. They infect only leguminous plants. Nodule bacteria are very specific. It happens that bacteria that form nodules on lupine roots do not infect the roots of peas or clover. But although they sometimes differ from each other, all nodule bacteria develop well in neutral soil acidity. They are used in agriculture to improve the value of soils and obtain better yields.

Escherichia coli

There are microorganisms that live in a completely different environment. These include a strain of the bacterium Escherichia coli, which lives in the human intestines. Bacteria enter the body of a newborn baby orally within 40 hours after birth.

E. coli, as it is called, brings certain benefits to the human body. It synthesizes vitamins K and B1, and also resists pathogenic bacteria that appear in our gastrointestinal tract from time to time. E. coli is used for genetic research because it can be isolated in the laboratory. For some time, E. coli can live outside the body of humans and animals - this allows samples to be analyzed for the presence of fecal contamination.

Mutants

Pathogenic microorganisms located in hospitals gradually form hospital strains. Their main feature is the ability to quickly infect the body. They are also multiresistant (have lightning-fast adaptation to drugs). Hospital infections can cause large-scale nosocomial diseases in a short time.

Among all microorganisms, scientists separately distinguish auxotrophs. They are distinguished by the fact that they cannot produce any organic matter necessary for their growth and development. Auxotrophs are mutants because they cannot develop independently if the necessary organic matter is not in the environment. These strains are used for various studies. Auxotrophs are also convenient to use for genetic marking in microbiology.

The concept of auxotrophy is not limited to microbiology. Many species on Earth are auxotrophic. An example of an auxotrophic organism is humans - they need essential amino acids for normal development.

bacilli

In Russian you can often find the word “bacillus”. This concept can mean both a genus of bacteria (Latin bacillus) and bacteria or microorganisms in general. The second option is more common in simple speech. In fact, bacilli are gram-positive, spore-forming bacteria that look like curved rods.

The most famous of them are:

Bacillus anthracis, which is the causative agent of anthrax;
Bacillus subtilis, also called Bacillus subtilis;
Bacillus cereus – causes toxic infections in humans, resulting in vomiting or diarrhea.

Benefits of bacilli

It is worth noting that among the bacilli there are microorganisms that maintain optimal microflora in our intestines. Bacillus strains are also used as active probiotics. They can be found in various medications and dietary supplements. Thus, in Russia you can find dietary supplements that include Bacillus subtilis. Examples of using the beneficial properties of bacilli are the drugs Baktistatin and Kinder gel. In the USA, the company produces a strain of Bacillus coagulans, which is used to produce the drug Sustenex.

The bacilli are used in agriculture because they produce antibiotics and have the ability to acidify the soil. They effectively counteract many microorganisms, such as salmonella, proteus, streptococci, and in addition, they produce amino acids and vitamins that plants need. Strains such as Bacillus subtilis and licheniformis are successfully used to obtain α-amylase and proteins (important components of enzymatic preparations)

Cereus IP 5832

Bacillus cereus IP 5832 is a non-pathogenic living microorganism. It is used as the main active ingredient to obtain drugs that restore optimal intestinal microflora. Some of its features:

Cereus IP 5832 counteracts pathogens and helps normalize digestion.
Bacillus cereus IP 5832 is present in medicines in the form of spores that are resistant to gastric acid and pepsin.
Already in the intestine, Cereus IP 5832 spores turn into full-fledged microorganisms through maturation.
Cereus IP 5832 is genetically close to Bacillus subtilis.
The Bacillus cereus strain IP 5832 resists many broad-spectrum antibiotics and restores normal intestinal microflora.

Cereus IP 5832 during normal development should not be in the human intestine, therefore 4 days after using preparations containing bacterial spores, it is excreted naturally.

Bacillus subtilis

Bacillus subtilis is one of the most studied microorganisms. Main properties:

Reproduces by division or spores.
Subtilis is a colorless, straight rod with rounded, blunt edges.

The bacillus was first isolated in 1835 by isolating it from a decoction of hay, hence its name.

Thanks to Bacillus subtilis, the mechanisms of sporulation of bacilli, the work of the flagellum of microorganisms were studied, and the genetic changes that occur in bacteria in space or conditions close to weightlessness were studied.

Bacillus subtilis

Subtilis, like other bacilli, has the ability to suppress pathogenic microorganisms. That is why predatory animals sometimes eat certain types of plants in which the hay bacillus can be found.

Bacillus subtilis is often among the first to appear in a human wound. It produces antibiotics that negatively affect the development of pathogens and has an antiallergic effect. Subtilis inhibits most pathogens of surgical infections.

Microorganisms are invisible to us, but they play a very important role in the life of all ecosystems on the planet. Bacteria produce organic substances, vitamins, and kill pathogenic microorganisms. We can use their properties to create many useful things. And then what seems fantastic today will be applied everywhere tomorrow.

I work as a veterinary doctor. I am interested in ballroom dancing, sports and yoga. I prioritize personal development and mastering spiritual practices. Favorite topics: veterinary medicine, biology, construction, repairs, travel. Taboos: law, politics, IT technologies and computer games.

Table of contents of the topic "Anthrax causative agent. Clinical manifestations of anthrax infection. Bacillus cereus.":

Bacillus cereus. Morphology of bacillus cereus. Cultural properties of bacillus cereus. Clinic of bacillus cereus poisoning. Principles of microbiological diagnosis of bacillus cereus. Identification of bacillus cereus.

Bacillus cereus- a soil saprophyte bacterium, widespread in nature. Bacteria often contaminate food products, causing food poisoning. The phenomena of intoxication are mediated by enterotoxin. It is formed by bacteria that grow from spores that are resistant to certain thermal processing conditions of food products (usually vegetables). Bacteria produce toxins only in vivo, during spore germination. In recent years, hospital infections sporadically caused by B. cereus have also been noted - bacteremia, endocarditis and meningitis in people with prosthetic organs, catheters, in patients with hemodynamic disorders, as well as in those who have been receiving cytostatics and immunosuppressants for a long time. The lesions are severe and often fatal.

Morphology and cultural properties of bacillus cereus

Morphologically Bacillus cereus resembles an anthrax bacillus; the main differences are mobility and hemolytic activity. In smears, bacteria are arranged in a picket fence pattern. Temperature optimum for growth is 30 °C; optimum pH 7-9.5. On agar, the pathogen forms “spread out” colonies with jagged edges; on the CA, the colonies are surrounded by a wide zone of hemolysis (see Fig. 4 inset). Over time, the colonies acquire a characteristic waxy appearance [from lat. now, wax, candle]. In liquid media, they form a delicate film on the surface, a white flaky sediment and cloudiness of the broth. Bacteria exhibit high proteolytic activity and liquefy gelatin in 1-4 days; all strains produce lecithinase and acetoin. They form acid in media containing glucose and maltose.

Clinical manifestations of bacillus cereus poisoning

Bacillus cereus causes two types of food poisoning (gastroenteritis).

Bacillus cereus poisoning the first type is characterized by a shortened incubation period (about 4-5 hours); Characterized by debilitating diarrhea and vomiting. The disease develops when eating food contaminated with a large number of microorganisms.

Bacillus cereus poisoning The second type of poisoning has a longer incubation period (about 17 hours). Patients complain of cramping abdominal pain and diarrhea. This set of symptoms is often mistaken for food poisoning caused by clostridia.

Principles of microbiological diagnosis of bacillus cereus

Diagnostic sign of bacillus cereus consider the detection in suspicious food products of more than 10 5 bacteria in 1 g/ml of product or 10 2 -10 3 bacteria in 1 g/ml of feces and vomit or washing water. The main differences between B. cereus and B. anthracis are hemolytic activity, motility, resistance to penicillin, rapid liquefaction of gelatin and non-pathogenicity for white mice.

(lat. Bactisubtil®) is a bacterial antidiarrheal drug.

The active ingredient of bactisubtil is bacilli strain IP 5832 (ATCC 14893) of the species Bacillus cereus- a microorganism close to Bacillus subtilis.

One capsule of bactisubtil contains 35 mg (10 9 spores) of dried powder of bacteria strain Bacillus cereus IP 5832.

Mechanism of action of bactisubtil

Bacillus spores Bacillus cereus, being resistant to gastric juice, pass intact into the intestines, where they are transformed into active forms that release broad-spectrum antibacterial substances that suppress the development of pathogenic and conditionally pathogenic bacteria, have an antimicrobial, antidiarrheal effect, and restore the intestinal microflora.

Baktisubtil has antimicrobial activity and can be used for bacterial infections when it is impossible to take antibiotics or for selective decontamination of the small intestine in bacterial overgrowth syndrome. The spores of these bacteria, turning into active forms in the colon, produce acidic metabolites - organic acids - during their life. At the same time, the pH shifts to the acidic side and the growth of pathogenic and opportunistic microorganisms is suppressed (E.A. Belousova, A.R. Zlatkina).

Indications for use of bactisubtil

acute and chronic diarrhea of various nature, including infectious
intestinal dysbiosis, including those caused by taking antibiotics
enteritis and enterocolitis
prevention and treatment of intestinal disorders caused by chemotherapy or radiotherapy.

How to take bactisubtil and dose

Bactisubtil is taken one hour before meals. Drink only cold liquid. Bactisuptil should not be taken in combination with alcohol. The duration of therapy with bactisubtil is 7-10 days.

Adults and adolescents take 2 capsules of bactisubtil 2-4 times a day.
Children over 7 years old take 1-2 capsules of bactisubtil 2-3 times a day.

If there is no improvement from treatment with bactisubtil within three days, further use is not advisable.

General information

Baktisubtil is a prescription medicine. Treatment with bactisubtil is permissible only as prescribed by a doctor.

The invention relates to the field of medicine, namely microbiology, and can be used in bacteriological laboratories to detect the antagonistic activity of the Bacillus cereus strain IP 5832 (ATCC 14893). Co-incubation is carried out in a physiological solution of the isolated strain of Bacillus cereus IP 5832 (ATCC 14893) in a pure culture and the isolated pure culture of an opportunistic pathogenic microorganism (OPM) from the patient's feces. The resulting mixture is sown using Gold onto nutrient agar with and without penicillin at a concentration of 0.01 U/ml, and if a decrease in the amount of UPM on the medium with penicillin is detected compared to the amount of UPM on the medium without it, the presence of antagonistic activity of the Bacillus cereus strain IP 5832 is determined (ATCC 14893) against the UPM strain, while the eubiotic is assessed as effective against the UPM strain isolated from the patient during testing for intestinal dysbiosis. The invention provides suppression of the Bacillus cereus strain IP 5832 (ATCC 14893) without compromising the germination of UPM test cultures. 3 tables

The invention relates to the field of medicine, namely microbiology, and can be used in bacteriological laboratories to identify the antagonistic activity of the Bacillus cereus strain IP 5832 (ATCC 14893) for the purpose of individual assessment of the effectiveness of eubiotics, the main active principle of which is the strain Bacillus cereus IP 5832 (ATCC 14893 ), in relation to opportunistic microorganisms isolated from a patient during a study for intestinal dysbiosis. The invention can also be used in gastroenterology for individual selection of eubiotics, the main active ingredient of which is the Bacillus cereus strain IP 5832 (ATCC 14893), in the treatment of intestinal dysbiosis.

Among drugs for correcting altered intestinal microbiocenosis, eubiotics, intended to suppress pathogenic and opportunistic microorganisms, occupy an important place. Most often, eubiotics include representatives of the genus Bacillus, which are not representatives of the normal intestinal microflora, are eliminated soon after withdrawal and are powerful antagonists of unrelated microorganisms due to the production of lysozyme, proteolytic enzymes and bacteriocins. It is known that bacilli most effectively suppress pathogenic enterobacteria and some opportunistic microorganisms that colonize the intestinal biotope: S. aureus, Candida spp., E. coli, P. aeruginosa, K. pneumoniae and other opportunistic enterobacteria.

One of the most widely used eubiotic drugs in many countries is the drug “Baktisubtil” (France), the main active ingredient of which is Bacillus cereus strain IP 5832 (ATCC 14893). The eubiotic “Flonivin” is also known, the main active ingredient of which is also Bacillus cereus strain IP 5832 (ATCC 14893), BS Manufacturer: Galenika, A.D., Serbia.

Industrial strains of the genus Bacillus do not form biofilms, since their adhesive properties to intestinal epithelial cells are weak. Based on the fact that the activity of the Bacillus cereus strain occurs in the intestinal lumen and is associated primarily with the high antagonistic activity of this strain, and not with competitive relationships for sites of attachment to the mucosa, then the effectiveness of eubiotics, the main active principle of which is the Bacillus cereus strain IP 5832 (ATCC 14893), in relation to opportunistic microorganisms isolated from a patient during the diagnosis of intestinal dysbiosis, can be judged by the presence or absence of antagonistic activity of the Bacillus cereus strain IP 5832 (ATCC 14893).

Bacteriocins or bacteriocin-like substances are produced by bacilli mainly extracellularly and are capable of accumulating in the nutrient medium. Thanks to this, theoretically, the antagonistic activity of bacilli can be detected using various modifications of direct or delayed antagonism methods, traditionally used only to detect antagonism of probiotic lacto- and bifidobacteria: the streak method, the Frederick delayed antagonism method with intermediate killing of the producer strain with chloroform, the double-layer agar method .

To identify the antagonistic activity of the Bacillus cereus strain IP 5832 (ATCC 14893), we used the above methods.

To assess the antagonistic activity of bacilli by the direct antagonism method, a suspension of a daily culture of B.cereus was streaked across the diameter of a Petri dish with nutrient agar at a concentration of 1×10 9 according to the optical turbidity standard GISC named after. L.A. Tarasevich. Cultures of opportunistic microorganisms isolated during the diagnosis of intestinal dysbiosis were sown perpendicularly. Incubated at 37°C for 24 hours. The presence of antagonistic activity was taken into account by the presence of growth retardation in the test strains.

When assessing the antagonistic activity of bacilli using the delayed antagonism method, test cultures of opportunistic microorganisms were inoculated 24 and 48 hours after inoculation of the bacilli.

In the considered options for assessing the antagonism of the Bacillus cereus strain IP 5832 (ATCC 14893), according to our own data, the strain did not exhibit antagonistic activity against test cultures of opportunistic microorganisms (80 strains). Some actively motile strains of opportunistic microorganisms (P. aeruginosa, E. coli) grew on the surface of bacillary colonies.

It is believed that bacilli metabolites have a more powerful antagonistic effect than live cultures. Therefore, we also used the method of delayed antagonism with intermediate killing of the producer strain with chloroform. Bacillus cereus strain IP 5832 (ATCC 14893) was inoculated into solidified 1.5% nutrient agar poured into Petri dishes and grown for 48 hours at 37°C. After incubation, the resulting culture was killed with chloroform vapor and a suspension of the test culture of the opportunistic microorganism was layered. To do this, 0.1 ml of culture in a final concentration of 10 8 cells according to the optical turbidity standard was mixed with 2.5-3 ml of 0.7% semi-liquid agar melted and cooled to a temperature of 46-48°C. If there is the ability to produce bacteriocins, a zone of growth inhibition of the test strain should be observed around the colony of the Bacillus cereus strain IP 5832 (ATCC 14893). Antagonistic activity of bacilli was not detected, because growth of test cultures of UPM “lawn” was noted on the surface of the medium with putative bacteriocins.

We obtained similar data using the method of modified double-layer agar with inoculation of bacilli with a lawn, followed by killing and layering of the UPM test culture.

The closest in technical essence to the claimed method is the inverted agar method, which is described for identifying the antagonistic activity of probiotics containing Bacillus subtilis and Escherichia coli against opportunistic yeast. To do this, strains of Bacillus subtilis and Escherichia coli are sown on a solid nutrient medium, after 2 days the agar is turned over and a pre-titrated seed dose of yeast is sown on its reverse side. Incubate for 24 hours under aerobic conditions at 37°C. The presence of antagonism is detected quantitatively by the suppression of yeast growth compared to a similar inoculation without probiotic strains.

The inverted agar method is described and tested to evaluate the antifungal effects of probiotics containing Bacillus subtilis and Escherichia coli. But the antagonistic effect on other opportunistic microorganisms (not opportunistic yeast) has not been assessed. In addition, the original method involves selecting a seed dose of yeast at which no more than 70 colonies would grow on agar. This requires titration and additional research when testing each strain. Testing this method using the eubiotic producer strain Bacillus cereus IP 5832 (ATCC 14893) and 80 test cultures of opportunistic microorganisms isolated during the diagnosis of intestinal dysbiosis did not allow us to identify a single case of antagonistic activity of the Bacillus cereus strain IP 5832 (ATCC 14893 ).

To assess the antagonistic activity of lacto- and bifido-containing probiotics, methods of co-cultivation in a liquid medium with various indirect assessment methods that do not imply subsequent seeding on a solid nutrient medium to determine the number of suppressed UPMs are also described.

Thus, none of the known methods for detecting the antagonistic activity of probiotic lacto- and bifidobacteria, according to the authors, allowed us to detect the antagonistic activity of the Bacillus cereus strain IP 5832 (ATCC 14893) against opportunistic microorganisms isolated from a patient during a study for intestinal dysbiosis .

In the literature, we also have not found a way to individually assess the effectiveness of the drug "Baktisubtil" or other eubiotic drugs, the main active principle of which is Bacillus cereus strain IP 5832 (ATCC 14893), against opportunistic microorganisms isolated from a specific patient during a study for dysbacteriosis intestines.

The objective of the invention is to identify the antagonistic activity of Bacillus cereus strain IP 5832 (ATCC 14893) against opportunistic microorganisms isolated from a particular patient during a study for intestinal dysbiosis.

The technical result of the invention is the suppression of the eubiotic strain Bacillus cereus IP 5832 (ATCC 14893) without compromising the germination of test cultures.

The technical result is achieved by isolating a pure culture of opportunistic microorganisms from the feces of the subject, then isolating Bacillus cereus strain IP 5832 (ATCC 14893) in a pure culture, after which the Bacillus cereus strain IP 5832 (ATCC 14893) is co-incubated with each of the strains of opportunistic microorganisms in physiological solution, followed by Gold seeding on nutrient agar with penicillin at a concentration of 0.01 U/ml and without it, and when identifying a decrease in the number of opportunistic microorganisms on a medium with penicillin compared to the number of opportunistic microorganisms microorganisms on a medium without penicillin, the presence of antagonistic activity of the strain Bacillus cereus IP 5832 (ATCC 14893) against a strain of an opportunistic microorganism is determined, while the eubiotic is assessed as effective against a strain of an opportunistic microorganism isolated from a given patient during a study for intestinal dysbiosis.

The method is carried out as follows:

Using standard methods, a pure culture of opportunistic microorganisms is isolated from the patient’s feces and Bacillus cereus strain IP 5832 (ATCC 14893) in a pure culture, which is the main active principle of the eubiotic. We isolated a pure culture of Bacillus cereus strain IP 5832 (ATCC 14893) from the eubiotic “Baktisubtil”. 1 ml of a suspension of a test culture of an opportunistic microorganism in physiological solution in a final concentration of 10 9 cells according to the optical turbidity standard is mixed with 1 ml of a suspension of Bacillus cereus in the same concentration. The mixture is incubated for 48 hours at 37°C. Then sowing is carried out according to Gold. To do this, quantitative seeding is carried out using a measuring loop with a diameter of 3 mm and a capacity of 2 μl on nutrient agar with penicillin at a concentration of 0.01 U/ml to suppress bacilli and on a medium without antibiotics to control the growth of both types of cultures. To exclude other possible factors suppressing the growth of UPM and bacilli (lack of a nutrient base), control sowing of monocultures is carried out in parallel after incubation under similar conditions. The number of grown microorganisms is calculated according to table 1 - Calculation table for determining the number of bacteria in 1 ml of liquid. If more than one UPM is detected from the patient's feces, the described procedure is carried out with each of the UPMs. If a decrease in the number of opportunistic microorganisms is detected on the medium with penicillin compared to the control seeding, the presence of antagonistic activity of the Bacillus cereus strain IP 5832 (ATCC 14893) is determined against the strain of the opportunistic microorganism isolated from the patient during the study for intestinal dysbiosis. The presence or absence of antagonistic activity of the Bacillus cereus strain IP 5832 (ATCC 14893) is an evaluation criterion for determining the effectiveness of eubiotics, the main active principle of which is Bacillus cereus strain IP 5832 (ATCC 14893), against a strain of an opportunistic microorganism isolated from a given patient during study for intestinal dysbiosis. In the presence of antagonistic activity of the Bacillus cereus strain IP 5832 (ATCC 14893), the eubiotic is assessed as effective against the strain of an opportunistic microorganism isolated from this patient during a test for intestinal dysbiosis.

The essential distinctive features of the proposed method are:

Isolate a pure culture of opportunistic microorganisms from the feces of the subject;

A pure culture of Bacillus cereus strain IP 5832 (ATCC 14893) is isolated, which is the main active principle of the eubiotic;

Then the Bacillus cereus strain IP 5832 (ATCC 14893) is co-incubated with each of the strains of opportunistic microorganisms in physiological solution;

Subsequent sowing of the mixture on a nutrient medium according to Gold;

Sowing is carried out on nutrient agar with and without penicillin at a concentration of 0.01 U/ml;

If a decrease in the number of opportunistic microorganisms on a medium with penicillin is detected compared to the number of opportunistic microorganisms on a medium without penicillin, the presence of antagonistic activity of the Bacillus cereus strain IP 5832 (ATCC 14893) against strains of opportunistic microorganisms is determined;

In the presence of antagonistic activity of the Bacillus cereus strain IP 5832 (ATCC 14893) against strains of opportunistic microorganisms, the eubiotic is assessed as effective against a strain of opportunistic microorganism isolated from a given patient during testing for intestinal dysbiosis.

The cause-and-effect relationship between the essential distinctive features and the achieved result:

The individuality of identifying the antagonistic activity of the Bacillus cereus strain IP 5832 (ATCC 14893) against opportunistic microorganisms, and, in turn, the individuality of assessing the effectiveness of eubiotics, the main active principle of which is Bacillus cereus strain IP 5832 (ATCC 14893) against opportunistic microorganisms microorganisms isolated from a patient during a study for intestinal dysbiosis are ensured by isolating opportunistic microorganisms in a pure culture from the feces of the subject and isolating a pure culture of Bacillus cereus strain IP 5832 (ATCC 14893), followed by joint incubation in saline and plating according to Gold onto a nutrient medium .

Sowing according to Gold on a nutrient medium is necessary to determine the number of suppressed UPMs.

Nutrient agar with penicillin at a concentration of 0.01 U/ml allows you to suppress the eubiotic strain of Bacillus cereus IP 5832 (ATCC 14893), without compromising the germination of test cultures, which makes it possible to detect the antagonistic activity of B. cereus against opportunistic microorganisms.

As test cultures, we studied strains of opportunistic microorganisms isolated from patients with intestinal dysbiosis - 20 isolates each of S. aureus, S. epidermidis, Klebsiella spp., E. coli with typical properties, E. coli with altered enzymatic activity, Enterobacter spp., Citrobacter spp., P. aeruginosa.

1 ml of a suspension of UPM test cultures in physiological solution at a final concentration of 10 9 cells according to the optical turbidity standard was mixed with 1 ml of a suspension of Bacillus cereus strain IP 5832 (ATCC 14893), at the same concentration. To avoid the proliferation of bacilli or opportunistic bacteria, the use of any liquid culture media for joint incubation was considered inappropriate. The mixture was incubated for 48 h at 37°C. It was assumed that during this time the UPM died out under the influence of bacilli metabolites. Quantitative seeding was carried out using a measuring loop with a diameter of 3 mm and a capacity of 2 μl according to Gold. They were sown on nutrient agar with antibiotics to suppress bacilli and on medium without antibiotics to control the growth of both types of cultures. To exclude other possible factors suppressing the growth of UPM and bacilli (lack of a nutrient base), control sowing of monocultures was carried out in parallel after incubation under similar conditions. The number of grown microorganisms was calculated according to table 1 - Calculation table for determining the number of bacteria in 1 ml of liquid 1.

To suppress the growth of bacilli on the seeding medium, a selective additive was previously selected - an antibiotic in a concentration that suppresses the bacilli, but does not inhibit the growth of microorganisms, based on data on the widespread resistance to penicillin and streptomycin among the tested opportunistic bacteria (especially enterobacteria). Different concentrations of antibiotics were added to nutrient agar melted and cooled to 46-48°C. When testing media with streptomycin, the drug was added at concentrations of 1.0 U/ml, 0.5 U/ml, 0.25 U/ml of medium. 25 cultures of UPM and Bacillus cereus strain IP 5832 (ATCC 14893) were inoculated at a concentration of 10 9 cells/ml on media with and without antibiotics. However, the growth of bacilli was not completely suppressed - from 10 9 to 10 4 cells/ml at a maximum streptomycin concentration of 1.0 U/ml of medium. At the same time, UPM cultures (Klebsiella spp., Enterobacter spp., atypical E. coli, Citrobacter spp., S. aureus) isolated during the diagnosis of dysbiosis were suppressed to varying degrees by streptomycin in 74 (96%) tests (Table 2 - Selection antibiotic to suppress Bacillus cereus strain IP 5832 (ATCC 14893) and the simultaneous growth of opportunistic microorganisms).

When testing media with penicillin, the drug was added at concentrations of 0.001 U/ml, 0.01 U/ml, 0.1 U/ml, 1.0 U/ml of medium. Sowing and recording of results were carried out similarly. Opportunistic enterobacteria were not suppressed even by a maximum penicillin concentration of 1.0 U/ml of medium. More intense suppression of S. aureus was observed. An acceptable level of germination of opportunistic bacteria, including S. aureus, with simultaneous complete suppression of the Bacillus cereus strain IP 5832 (ATCC 14893) was observed at a penicillin concentration of 0.01 U/ml of nutrient medium (Table 2 - Selection of antibiotic for suppression of the Bacillus strain cereus IP 5832 (ATCC 14893) and the simultaneous growth of opportunistic microorganisms).

In the presence of antagonistic activity of Bacillus cereus strain IP 5832 (ATCC 14893) against opportunistic microorganisms, the eubiotic is assessed as effective against a strain of opportunistic microorganism isolated from a given patient during testing for intestinal dysbiosis.

We selected the antagonistic activity of the Bacillus cereus strain IP 5832 as an evaluation criterion for individual assessment of the effectiveness of eubiotics, the main active principle of which is Bacillus cereus strain IP 5832 (ATCC 14893), in relation to a strain of opportunistic microorganism isolated from this patient during a study for intestinal dysbiosis. (ATCC 14893). This is explained by the fact that the activity of the Bacillus cereus strain occurs in the intestinal lumen and is associated primarily with the high antagonistic activity of this strain, and not with competitive relationships for sites of attachment to the mucosa.

The set of essential distinctive features of the proposed method is new and makes it possible to suppress the eubiotic Bacillus cereus strain IP 5832 (ATCC 14893) without compromising the germination of test cultures, which, in turn, ensures the identification of the antagonistic activity of the eubiotic strain Bacillus cereus IP 5832 (ATCC 14893) in in relation to opportunistic microorganisms isolated during a study for intestinal dysbiosis from a patient, which can be used for individual assessment of the effectiveness of eubiotics, the main active principle of which is Bacillus cereus strain IP 5832 (ATCC 14893), in relation to opportunistic microorganisms isolated from a patient when examining for intestinal dysbiosis.

Examples of specific implementation:

A bacteriological examination of stool for intestinal dysbiosis (No. 247) revealed Citrobacter freundii in an amount of 5×10 6 CFU/g.

1 ml of a suspension of a pure culture of Citrobacter freundii, isolated from the patient's feces, in physiological solution at a final concentration of 10 cells according to the optical turbidity standard was mixed with 1 ml of a suspension of a pure culture of Bacillus cereus strain IP 5832 (ATCC 14893), isolated from the eubiotic "Bactistatin", in the same concentration. The mixture was incubated for 48 h at 37°C. Then quantitative seeding was carried out with a measuring loop with a diameter of 3 mm and a capacity of 2 μl in Gold onto nutrient agar with penicillin at a concentration of 0.01 U/ml to suppress bacilli and onto a medium without antibiotics to control the growth of both types of cultures. The number of grown microorganisms was calculated according to Table 1 - Calculation table for determining the number of bacteria in 1 ml of liquid.

In the control variant, the concentration of Citrobacter freundii was 10 8 CFU/g, in the experimental variant 5 × 10 CFU/g. The antagonistic activity of the Bacillus cereus strain IP 5832 (ATCC 14893) against the Citrobacter freundii strain (No. 247) was revealed. The drug "Baktisubtil" is determined to be effective against the strain of Citrobacter freundii isolated from a patient during a study for intestinal dysbiosis.

A bacteriological examination of stool for intestinal dysbiosis (No. 512) revealed S aureus in an amount of 10 6 CFU/g.

1 ml of a suspension of a pure culture of S aureus isolated from the patient’s feces in physiological solution at a final concentration of 10 9 cells/ml according to the optical turbidity standard was mixed with 1 ml of a suspension of a pure culture of Bacillus cereus strain IP 5832 (ATCC 14893), isolated from the eubiotic “Bactisubtil” ", in the same concentration. The mixture was incubated for 48 h at 37°C. Then quantitative seeding was carried out with a measuring loop with a diameter of 3 mm and a capacity of 2 μl in Gold onto nutrient agar with penicillin at a concentration of 0.01 U/ml to suppress bacilli and onto a medium without antibiotics to control the growth of both types of cultures. The number of grown microorganisms was calculated according to Table 1 - Calculation table for determining the number of bacteria in 1 ml of liquid.

In the control variant, the concentration of S aureus was 5×10 6 CFU/g, in the experimental variant - 10 6 CFU/g. Antagonistic activity of the Bacillus cereus strain IP 5832 (ATCC 14893) against the S aureus strain was not detected (no. 512). The drug "Baktisubtil" is determined to be ineffective against the S aureus strain isolated from a patient during a test for intestinal dysbiosis.

A bacteriological examination of stool for intestinal dysbiosis (No. 429) revealed Klebsiella pneumoniae in the amount of 10 4 CFU/g, Enterobacter agglomerans in the amount of 10 6 CFU/g, Citrobacter freundii in the amount of 10 6 CFU/g, Staphylococcus aureus in the amount of 10 4 CFU/g. G.

1 ml of a suspension of a pure culture of each of the strains of opportunistic microorganisms isolated from a patient, in physiological solution at a final concentration of 10 9 cells according to the optical turbidity standard, was mixed with 1 ml of a suspension of a pure culture of Bacillus cereus strain IP 5832 (ATCC 14893), isolated from a eubiotic " Baktisubtil" in the same concentration. Thus, 4 mixtures of strains of opportunistic microorganisms and bacilli were obtained. The mixtures were incubated for 48 h at 37°C. Then, quantitative seeding was carried out using a measuring loop with a diameter of 3 mm and a capacity of 2 μl in Gold onto nutrient agar with penicillin at a concentration of 0.01 U/ml to suppress bacilli and onto a medium without antibiotics to control the growth of each of the isolated cultures. The number of grown microorganisms was calculated according to Table 1 - Calculation table for determining the number of bacteria in 1 ml of liquid.

In the control variant, the concentration of Klebsiella pneumoniae was 10 8 CFU/g, in the experimental variant 10 6 CFU/g. In the control variant, the concentration of Enterobacter agglomerans was 10 7 CFU/g, in the experimental variant 10 5 CFU/g. In the control variant, the concentration of Staphylococcus aureus was 10 8 CFU/g, in the experimental variant 5×10 6 CFU/g. In the control variant, the concentration of Citrobacter freundii was 10 7 CFU/g, in the experimental variant 10 6 CFU/g.

The antagonistic activity of the Bacillus cereus strain IP 5832 (ATCC 14893) against the strains of Klebsiella pneumoniae, Enterobacter agglomerans, Staphylococcus aureus, Citrobacter freundii was revealed. The drug "Baktisubtil" is determined to be effective against these strains isolated from a given patient during a study for dysbacteriosis.

A bacteriological examination of stool for intestinal dysbiosis (No. 449) revealed Enterobacter agglomerans in the amount of 10 6 CFU/g, Klebsiella pneumoniae in the amount of 5×10 4 CFU/g, Citrobacter freundii in the amount of 10 6 CFU/g.

1 ml of a suspension of a pure culture of each of the isolated strains of opportunistic microorganisms in physiological solution at a final concentration of 10 9 cells according to the optical turbidity standard was mixed with 1 ml of a suspension of a pure culture of Bacillus cereus strain IP 5832 (ATCC 14893), isolated from the eubiotic "Baktisubtil", in the same concentration. Thus, 3 mixtures of strains of opportunistic microorganisms and bacilli were obtained. The mixtures were incubated for 48 h at 37°C. Then, quantitative seeding was carried out using a measuring loop with a diameter of 3 mm and a capacity of 2 μl in Gold onto nutrient agar with penicillin at a concentration of 0.01 U/ml to suppress bacilli and onto a medium without antibiotics to control the growth of each of the isolated cultures. The number of grown microorganisms was calculated according to Table 1 - Calculation table for determining the number of bacteria in 1 ml of liquid.

In the control variant, the concentration of Enterobacter agglomerans was 10 8 CFU/g, in the experimental variant 5×10 7 CFU/g. In the control variant, the concentration of Klebsiella pneumoniae was 10 7 CFU/g, in the experimental variant 5×10 6 CFU/g. In the control variant, the concentration of Citrobacter freundii was 10 7 CFU/g, in the experimental variant 5×10 5 CFU/g.

The antagonistic activity of the Bacillus cereus IP 5832 (ATCC 14893) strain against the Citrobacter freundii strain was revealed; the antagonistic activity of the Bacillus cereus IP 5832 (ATCC 14893) strain against the Enterobacter agglomerans and Klebsiella pneumoniae strains was not detected. The drug "Baktisubtil" is determined to be effective against the strain of Citrobacter freundii and ineffective against the strains of Enterobacter agglomerans and Klebsiella pneumoniae isolated from this patient during a study for dysbacteriosis.

A bacteriological examination of stool for intestinal dysbiosis (No. 461) revealed Klebsiella pneumoniae in an amount of 10 6 CFU/g and Citrobacter freundii in an amount of 10 6 CFU/g.

1 ml of a suspension of a pure culture of each of the isolated strains of opportunistic microorganisms in physiological solution at a final concentration of 10 9 cells according to the optical turbidity standard was mixed with 1 ml of a suspension of a pure culture of Bacillus cereus strain IP 5832 (ATCC 14893), isolated from the eubiotic "Baktisubtil", in the same concentration. Thus, we obtained 2 mixtures of strains of opportunistic microorganisms and bacilli. The mixtures were incubated for 48 h at 37°C. Then, quantitative seeding was carried out using a measuring loop with a diameter of 3 mm and a capacity of 2 μl in Gold onto nutrient agar with penicillin at a concentration of 0.01 U/ml to suppress bacilli and onto a medium without antibiotics to control the growth of all isolated cultures. The number of grown microorganisms was calculated according to Table 1 - Calculation table for determining the number of bacteria in 1 ml of liquid.

In the control variant, the concentration of Klebsiella pneumoniae was 10 7 CFU/g, in the experimental variant 5×10 5 CFU/g. In the control variant, the concentration of Citrobacter freundii was 10 8 CFU/g, in the experimental variant 5×10 7 CFU/g.

The antagonistic activity of the Bacillus cereus IP 5832 (ATCC 14893) strain against the Klebsiella pneumoniae strain was revealed, and the antagonistic activity of the Bacillus cereus IP 5832 (ATCC 14893) strain against the Citrobacter freundii strain was not detected. The drug "Baktisubtil" is determined to be effective against the Klebsiella pneumoniae strain and ineffective against the Citrobacter freundii strain isolated from this patient during a study for dysbacteriosis.

Using a developed medium with penicillin at a concentration of 0.01 U/ml, we studied the antagonism of the Bacillus cereus strain IP 5832 (ATCC 14893) and 96 UPM cultures isolated in significant quantities during the study for intestinal dysbiosis: Citrobacter spp. (16 strains), Klebsiella spp. (17), S. aureus (18), Enterobacter spp. (15), typical E. coli (15), E. coli with atypical properties (15). The antagonistic activity of the eubiotic was assessed by the number of strains of tested microorganisms it suppressed (in%) (Table 3 - Antagonism of the Bacillus cereus strain IP 5832 (ATCC 14893) and opportunistic microorganisms).

Studies have shown that the studied Bacillus cereus strain IP 5832 (ATCC 14893) suppresses 17.7% (17 isolates) of the tested UPM strains.

However, the decrease in the number of opportunistic microorganisms was insignificant - by 0.5-2 lg. 79.0% (81 isolates) of the tested strains turned out to be resistant and even capable of reproduction in the presence of a eubiotic.

The inventive method makes it possible to suppress the eubiotic strain Bacillus cereus strain IP 5832 (ATCC 14893) without compromising the germination of test cultures, which, in turn, ensures the identification of the antagonistic activity of the eubiotic strain Bacillus cereus IP 5832 (ATCC 14893) against a strain of opportunistic microorganism , isolated during the diagnosis of intestinal dysbiosis in a patient, which can be used for individual assessment of the effectiveness of eubiotics, the main active principle of which is Bacillus cereus strain IP 5832 (ATCC 14893), against opportunistic microorganisms isolated from the patient during a study for intestinal dysbiosis.

Table 1
Calculation table for determining the number of bacteria in 1 ml of liquid
A	I	II	III	Quantity in 1 ml
1-6	-	-		<1000
8-20	-	-	-	3000
20-30	-	-	-	5000
30-60	-	-	-	10000
70-80	-	-	-	50000
100-150	5-10	-	-	100000
not counting	20-30	-	-	500000
-"-	40-60	-	-	1 million
-"-	100-150	10-20	-	5 million
-"-	not counting	30-40	-	10 million
-"-	-"-	60-80	Single colonies	100 million

Table 2
Selection of an antibiotic to suppress the Bacillus cereus strain IP 5832 (ATCC 14893) and the simultaneous growth of opportunistic microorganisms
Growth of UMR at a given antibiotic concentration, CFU/ml	Number of UPM strains grown at a given antibiotic concentration, abs (%)
Streptomycin, units/ml medium	Penicillin, units/ml medium
1,0	0,5	0,25	1,0	0,01	0,01	0,001
10 8 (identical to control)	1 (4)	8 (32)	10 (40)	16 (64)	19 (76)	22 (88)	23 (92)
10 6	4 (16)	2 (8)	0	4 (16)	3 (12)	3 (12)	2 (8)
10 5	15 (60)	12 (48)	15 (60)	5 (20)	3 (12)	0	0
10 4	3 (12)	3(12)	0	0	0	0	0
<10 4	2 (8)	0	0	0	0	0	0
Growth of Bacillus cereus at a given antibiotic concentration, CFU/ml	10 4	10 4	10 4	Ots.	Ots.	Ots.	10 4

Table 3
Antagonism of Bacillus cereus strain IP 5832 (ATCC 14893) and opportunistic microorganisms
Test cultures UPM	Number of strains	Susceptible strains abs (%)	Resistant strains abs (%)*
Reduction by 1 lg	Decrease by 2 lg	Total resistant strains	Of these, they are capable of growth in the presence of a eubiotic**
Klebsiella spp.	17	1 (5,9)	0	16(94,1)	1 (6.25)
Enterobacter spp.	15	4 (26,7)	1 (6,6)	10 (66,7)	1(10)
Citrobacter spp.	16	5(31,3)	0	11 (68,7)	1 (9,1)
typical E. coli	15	1 (6,7)	0	14 (93,3)	0
atypical E. coli	15	2(13,3)	0	13 (86,7)	1 (7,7)
S. aureus	20	3 (15,0)	0	17 (85,0)	6 (35,3)
* - the number of UPM did not change compared to the control or changed by no more than 0.5 lg ** - the number of UPMs increased compared to the control

Sources of information

1. Osipova I.G., Mikhailova R.A., Sorokulova I.B., Vasilyeva E.A., Gaiderov A.A. Spore probiotics // Journal of microbiology, virology and immunology. - 2003. - No. 3. - P.113-119.

2. Blinkova L.P., Semenova S.A., Butova L.G. and others. Antagonistic activity of freshly isolated strains of bacteria of the genus Bacillus // Journal of microbiology, virology and immunology. - 1994. - No. 5. - P.71-75.

3. Strains of bacteria Bacillus subtilis and Bacillus licheniformis, used as components of a drug against viral and bacterial infections, and a drug based on these strains. / Patent RU 2142287, publ. 12/10/99. - Bull. N20.

4. A strain of Bacillus subtilis bacteria with a wide spectrum of antagonistic activity. / Patent RU N2182172, publ. 05/10/02.

5. Gataullin A.G., Mikhailova N.A., Blinkova L.P., Romanenko E.E., Elkina S.I., Gaiderov A.A., Kalina N.G. Properties of isolated Bacillus subtilis strains and their effect on the intestinal microflora of experimental mice // Journal of Microbiology, Virology and Immunology. - 2004. - No. 2. - P.91-94.

6. Davydov D.S., Mefed K.M., Osipova I.G., Vasilyeva E.A. Worldwide use of spore probiotics in healthcare practice // Clinical nutrition. - 2007. - No. 1-2. - S.A36.

7. Sorokulova I.B. The influence of probiotics from bacilli on the functional activity of macrophages // Antibiotics and chemotherapy. - 1998. - No. 2. - P.20-23.

8. Blinkova L.P. Bacteriocins: criteria, classification, properties, detection methods // Journal of Microbiology, Virology and Immunology. - 2003. - No. 3. - P.109-113.

9. Postnikova E.A., Efimov B.A., Volodin N.N., Kafarskaya L.I. Search for promising strains of bifidobacteria and lactobacilli for the development of new biological products // Journal of microbiology, epidemiology and immunology. - 2004. - No. 2. P.64-69.

10. Gratia A., Fredericq P. Deversite des souches antibiotiques de Escherichia coli et étendue varibile de leur champ d'action. Ibid: 1031-1033.

11. Fredericq P. Actions antibiotiques reciproques chez les Enterobacteriaceae. REV. Belge Pathol. Med. Exp.1948, 19(Suppl. 4): 1-107.

12. Ermolenko E.I., Isakov V.A., Zhdan-Pushkina S.Kh., Tets V.V. Quantitative assessment of the antagonistic activity of lactobacilli // Journal of microbiology, virology and immunology. - 2004. - No. 5. - P.94-98.

13.Ushakova N.A., Chernukha B.A. The influence of temperature shock on the biological effectiveness of the probiotic Bacillus subtilis 8130 // Clinical nutrition. - 2007. - No. 1-2. - S.A70.

14. Arzumanyan V.G., Mikhailova N.A., Gaiderov A.A., Basnakyan I.A., Osipova I.G. A quantitative method for assessing delayed antagonism of probiotic cultures against opportunistic yeasts // Clinical laboratory diagnostics. - 2005. - No. 5. P.53-54.

15. Method for determining the antagonistic activity of probiotics. / RU Patent No. 2187801, publ. 08/20/2002.

16. Zykova N.A., Molokeeva N.V. New probiotic drug “Trilact” // Clinical nutrition. - 2007. - No. 1-2. - S.A42.

17. Guidelines for the use of unified microbiological (bacteriological) research methods in clinical diagnostic laboratories: Appendix 1 to the order of the USSR Ministry of Health No. 535. - 1986.

18. Sanford Jay P., Gilbert David N., Moeliering Robert C. Jr., Sande Merle A. Twenty-ninth edition The Sanford Guide to antimicrobial therapy, 1999.

FORMULA OF THE INVENTION

A method for individual assessment of the effectiveness of eubiotics, the main active principle of which is Bacillus cereus strain IP 5832 (ATCC 14893), against opportunistic microorganisms isolated from a patient during a study for intestinal dysbiosis, which consists in isolating opportunistic microorganisms in pure culture from the feces of the subject, then Bacillus cereus STRAIN IP 5832 (ATCC 14893) is isolated in pure culture, after which the Bacillus cereus strain IP 5832 (ATCC 14893) is co-incubated with each of the strains of opportunistic microorganisms in physiological solution, followed by sowing according to Gold on nutrient agar with and without penicillin at a concentration of 0.01 U/ml, and if a decrease in the number of opportunistic microorganisms on a medium with penicillin is detected compared to the number of opportunistic microorganisms on a medium without penicillin, the presence of antagonistic activity of the Bacillus cereus strain IP 5832 is determined (ATCC 14893) against a strain of an opportunistic microorganism, wherein the eubiotic is assessed as effective against a strain of an opportunistic microorganism isolated from a given patient when tested for intestinal dysbiosis.

The drug Baktisubtil was created specifically within the framework of the microbiological safety program by the French pharmaceutical company Patheon France. The probiotic is effective both in the treatment of gastrointestinal diseases and for preventive purposes. Promotes the rapid restoration of disturbed intestinal microflora, normalizes metabolic processes in the body, and improves immunity.

The effectiveness of Baktisubtil has been proven by clinical studies. The drug has a powerful effect, completely restoring the structure of the disturbed microflora of the gastrointestinal tract, and has a wide spectrum of action.

The preparation contains bacteria of the Bacillus cereus IP 5832 strain in dried form. Spores of beneficial bacteria are resistant to gastric juice, so they freely enter the small and large intestines in an active form. Suppress opportunistic and pathogenic microorganisms.
In addition, the product contains calcium carbonate and kaolin. The capsule shell is made of titanium dioxide and edible gelatin.   Gelatin capsules are white.

Action of Baktisubtil

The normal microflora of the gastrointestinal tract is effectively and quickly restored. The probiotic has a bacterial antidiarrheal and antimicrobial effect.
The body's defenses increase. Diseases of the intestines, respiratory organs, pancreas, and stomach are prevented.
Disturbed food processes are normalized.
Toxins and breakdown products are removed.
The manifestations of peptic ulcers, pancreatitis, gastritis, intestinal and vaginal dysbiosis are reduced.
Prevents disruption of synthesis.
Has a detoxifying effect.
Promotes the formation of B vitamins
The incidence of infectious and respiratory diseases is decreasing.
The drug is indicated for the treatment and prevention of diseases in children from the first days of life.

Indications for use

diarrhea, including in the treatment of dysbiosis;
impaired metabolism;
immunodeficiency state;
bacterial diseases of the gastrointestinal tract;
to eliminate symptoms of intestinal and vaginal imbalance at any stage;
hepatitis, peptic ulcer;
with bacterial overgrowth syndrome;
stressed gut;
enteritis, enterocolitis;
increased gas formation;
allergies to chemical, household, food, plant irritants;
with excess body weight;
chronic constipation;
in case of poisoning, including alcohol;
for chronic fatigue syndrome;
after radiation therapy or a course of treatment with antimicrobial drugs, antibiotics.

The course of treatment is from 1 to 4 weeks, depending on the severity of symptoms. If necessary, the course can be increased on the recommendation of the attending physician.

For acute intestinal disease - one capsule 4-6 times a day, starting from 12 years of age. In acute cases of the disease, take up to 10 capsules per day, but no more.

Children from 3 to 12 years old – 1 capsule 3-4 times a day.
Children under three years of age – 1-2 capsules per day.
For chronic diseases or for preventive purposes - 1 capsule 2 times a day.

Feature: Infants need to dilute the contents of the capsule in a small amount of breast milk, room temperature water, infant formula or juice. Do not dilute in hot drink!

Side effects

Allergy to any of the components included in the probiotic - rashes, itching, allergic rhinitis, laryngeal swelling, redness of the skin.

Bactisubtil does not cause side effects at recommended dosages.

Contraindications

1. Hypersensitivity to the active substance of the drug.
2. AIDS.
3. During transplantation.

Interactions with drugs

The probiotic can be taken simultaneously with sulfonamide drugs or antibiotics.
When interacting with ethanol, the effect of the drug is reduced, therefore it is not recommended to drink alcoholic beverages during treatment with Bactisubtil.

Use of the product during pregnancy and lactation period

Bactisubtil is one of the few drugs that has no contraindications during pregnancy or breastfeeding. This is explained by the fact that the components included in its composition do not have the ability to accumulate in the body, so the possibility of their penetration into breast milk or the placenta is excluded.

Analogs

In terms of structure, which is as close as possible to Bactisubtil, there are no analogues. However, there are probiotics that have similar pharmacological effects and provide no less positive medicinal effects.

When choosing analogues, the following characteristics should be taken into account:

in case of a viral nature of the gastrointestinal tract disorder, it is necessary to choose products with a high content of lactobacilli;
if a bacterial infection is suspected, combined synbiotic preparations containing both bifidobacteria and lactobacilli are suitable;
for fungal infections of the gastrointestinal tract, products containing bifidobacteria are prescribed.

Probiotics differ in their effect on the body, the quantitative and qualitative composition of beneficial microorganisms, and in cost.

Comparative characteristics of some analogues of Baktisubtil

Linux. Like Baktisubtil, it promotes the rapid restoration of damaged microflora. Linex has the following differences: it simultaneously contains three components - bifidobacteria, lactobacilli, and enterococcus. Therefore, it is recognized as a more effective drug in the treatment of dysbiosis.
Bifiform. Contains bifidobacteria and enterococci. Has a similar range of actions. Contraindication – hypersensitivity to any component.
Enterofuril. Refers to antimicrobial drugs prescribed in the treatment of infectious intestinal diseases. More effective for diarrhea, but less effective in treating dysbiosis.
Bactistatin. A complex probiotic made from freeze-dried yeast. Quickly suppresses putrefactive processes, accelerates the death of harmful bacteria and fungi. Recommended for diarrhea of any origin. Ineffective against dysbacteriosis.
Probifor. An antimicrobial drug with a broad spectrum of action. Active against many gram-positive enterobacteria. Indicated in the treatment of bacterial infections, diarrhea.
Lactobacterin. Contains a high amount of lactobacilli. Recommended for somatic diseases of the gastrointestinal tract, complicated by dysbacteriosis, for ulcerative and chronic colitis, in prenatal preparation to eliminate the risk of developing septic complications.
Primadophilus. A biologically active food supplement with restorative properties, a broad-spectrum synbiotic. The drug prevents the development of putrefactive and pyogenic flora in the intestines, enhances peristalsis, and stimulates the production of vitamins. Recommended for vaginal and intestinal dysbiosis, diarrhea, after a long course of antibiotics, rotavirus infections, food allergies, unbalanced nutrition, and any forms of diathesis in children.

The following drugs are also alternatives to Bactisubtil:

Colibacterin;
Gastrofarm;
Acylact;
Flonivin BS;
Regulin;
Advantan;
Dialin;
Algilak;
Uzara;
Symbiolact;
Biosporin;
Legkolaks;
Enterol;
Stoperan;
Diarrhea;
Acipol;
Carbolong;
Florin ForteSeñor;
Stopdiar;
Eubicor;
Orsol.

In the course of clinical and microbiological studies of Baktisubtil, conclusions were drawn: the drug quickly changes the intracavitary environment of the colon, promotes positive changes in the microbiocenosis of the gastrointestinal tract, and is effective in the treatment and prevention of dysbiotic disorders.